Bayer HealthCare reports positive VEGF Trap-Eye trial results

Bayer HealthCare has published new clinical data which supports the efficacy of VEGF Trap-Eye, its new treatment for eye diseases and disorders.

In association with collaborative partner Regeneron, the company conducted a phase III trial which evaluated the drug as a therapy for patients with macular edema due to central retinal vein occlusion.

It was found that the treatment was able to deliver significant improvements to patients' vision when compared to a placebo injection.

This comes in the same week that the companies also reported data from a phase II study that demonstrated VEGF Trap-Eye's efficacy in treating diabetic macular edema.

Dr Kemal Malik, head of global development for Bayer HealthCare, stated that it is now focusing on preparing regulatory filings for the drug as a treatment for the neovascular form of age-related macular degeneration, which will be submitted in 2011.

Earlier this month, Bayer HealthCare announced that it has applied for European approval of a new contraceptive regimen for women based on its drug Yaz.